Durvalumab for previously untreated,hepatocellular carcinoma

Durvalumab is in clinical development for previously untreated patients with hepatocellular carcinoma (HCC), the most common type of liver cancer that develops in liver cells known as hepatocytes. Typically, this type of cancer occurs in patients with underlying chronic liver disease and scarring of the liver caused by long-term liver damage (cirrhosis), as a result of viral infection or lifestyle factors such as high alcohol intake and obesity. Currently, there are a limited number of effective therapies available to treat patients with HCC, and their overall survival prognosis is poor due to rapid disease progression. Therefore, there is a need to develop more effective medicinal products for these patients.
Durvalumab is